ProductLife acquires Axpharma
Specialist provider of regulatory and compliance services for the life sciences industry, ProductLife Group (PLG)
(www.productlifegroup.com), has today announced the acquisition of pharmacovigilance services provider, Axpharma (www.axpharma.com) in response to a growing focus on safety, quality and speed to market during the continuing pandemic.
The acquisition is in line with PLG’s growth acceleration and transformation plan, supporting the Group’s ambition to be the leading global provider of regulatory and compliance services in life sciences – with offerings spanning regulatory affairs, safety, quality, compliance and pharmacovigilance (PV). PV services, in particular, are currently facing strong and growing international demand from life sciences companies and PLG’s PV capabilities will be strongly bolstered via the Axpharma deal.
Founded in 2001, Axpharma is a prominent pharmacovigilance service provider in Europe. Its team of experts enjoys a strong reputation for providing highly dependable services in the areas of pharmacovigilance responsibility, case management, literature research, medical writing and around-the-clock medical information. Its clients include pharmaceutical, biopharmaceutical medical device and cosmetics companies.
Commenting on the Axpharma acquisition, PLG CEO Xavier Duburcq says, “The merger of PLG and Axpharma offers tremendous potential to further invest in automation and artificial intelligence, as part of our aim to offer reliable, innovative, and cost-effective solutions to our clients that are always one step ahead of what the industry expects. I have known Axpharma for some years and our positive, proactive cultures are a great match.”
“We are excited at the prospect of being part of a larger group with an excellent reputation and a broader reach,” adds Sophie Brisset-Jaillet, Managing Director, Axpharma. “This is an exciting step for Axpharma, and we are all working hard to ensure a smooth and efficient transition.”
ProductLife Group has enjoyed robust commercial success in 2020, including some notable COVID-19 safety projects and a significant deal to manage the regulatory and quality activities of a large generic-drug organization.